Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0268596 (EMA)
 2,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Erythrocyte-stage Babesia equi expresses a 34-kDa immunodominant antigen recognized by antibody from persistently infected horses worldwide. This erythrocyte-stage surface protein, equi merozoite antigen-1 (EMA-1) is encoded by a single copy gene, and was previously shown to share 33% amino acid identity with similar sized proteins of Theileria sergenti and T. buffeli. A mean homology of 31% amino acid identity extends to similar sized proteins of T. parva, T. annulata and T. mutans. Genomic and cDNA copies of a second B. equi gene, ema2 were cloned. The single copy ema2 gene encodes a 30-kDa protein (EMA-2) that shares 52% amino acid identity with EMA-1. EMA-2 also shares a mean amino acid identity of 31% with proteins of similar molecular mass from Theileria species. EMA-1 and EMA-2 each contain a glycosylphosphatidylinositol anchor. These unique erythrocyte-stage surface proteins of B. equi and Theileria species lack antigenic repeats, and excluding the signal peptide, contain one or no cysteines. Consistent with the hypothesis that this family of proteins interacts with the erythrocyte surface, the T. species proteins possess a basic isoelectric point. The B. equi proteins have acidic isoelectric points, but 24-mer peptides within them have strongly basic net charges.
 ...
PMID:Genetic and biochemical analysis of erythrocyte-stage surface antigens belonging to a family of highly conserved proteins of Babesia equi and Theileria species. 949 33

Coeliac disease (CD) is a systemic autoimmune disorder triggered by gluten consumption in genetically susceptible individuals. It exhibits several clinical features, such as blood auto-antibodies (anti-endomysial antibodies EMA, anti-transglutaminase antibodies tTG, anti-deamidated gliadin peptides PGD), plus variable degrees of damage in the small intestinal mucosa. In Chile, tTG is positive in 0.76% in individuals >15 years, with the prevalence of CD being estimated at 0.6%. Approximately17% of first-degree relatives of coeliac patients have been reported tTG positive. To date, the gluten free diet (GFD) is the only known treatment for CD. To be effective, this must be lifelong, permanent, and strict. Gluten content in the GFD is not zero, but is limited to a cut-off of 3ppm (ormg/kg of product) in Chile. Mortality higher than that of the general population has been reported among coeliac patients, and poor adherence to GFD is associated with complications (mainly autoimmune processes and cancer). GFD is difficult to maintain strictly and poor adherence is by far the main cause of lack of response to treatment. Follow-up of adherence is also difficult because there are no objective measurements to assess it. In clinical practice determination of serum EMA, tTG and PGD is routinely used for these purposes, although more recently, the interview by an expert dietitian, validated questionnaires and measurement of faecal 33-mer peptide are being assessed as alternatives or complements to measure adherence to GFD. A review is presented with the current concepts on the available tools to follow up patients on GFD, emphasising those available in Chilel.
 ...
PMID:[Treating coeliac disease. How do we measure adherence to the gluten-free diet?] 2692 2